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Highlights: 
 High risk ALL patients experience significant adverse events during induction  
 Factors predictive of prolonged hospital stay during induction were identified  
 Outpatient management of new ALL patients is often not feasible or safe   
 An aggressive and close outpatient follow up of these patients is indicated  
 
Abstract 
Background: 
High Risk (HR) or Very High Risk (VHR) acute lymphoblastic leukemia (ALL) treated 
with 4 drug induction chemotherapy is often associated with adverse events.  The aim 
of this study was to identify risk factors associated with a prolonged inpatient length of 
stay LOS during induction chemotherapy.    
Procedure: 
Data from patients (N=73) (age<21 years) was collected through a retrospective chart 
review. Univariable and multivariable logistic regression was used to test for statistical 
significance. The overall survival and disease (leukemia)-free survival were analyzed 
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using the Kaplan–Meier method and log-rank test. 
Results: 
Of the 73 patients, 42 (57%) patients were discharged on day 4 of induction (short LOS, 
group A), while 31 (43%) patients (group B) experienced a prolonged LOS or an ICU 
stay (16 ± 27.7 days, median hospital stay=8 days vs 4 days (group A), p=0.02) due to 
organ dysfunction, infectious or metabolic complications. Group B patients were more 
likely to have a lower platelet count, serum bicarbonate, and a higher blood urea 
nitrogen (BUN) on day 4 of treatment (OR=4.52, 8.21, and 3.02, respectively, p<0.05). 
Multivariable analysis identified low serum bicarbonate (p=0.002) and a platelet 
count<20,000/µL (p=0.02) on day 4 of induction to be predictive of a prolonged LOS. 
Twenty six (group A (n=16, 36%) and B (n=11, 35%), p =0.8) patients experienced 
unplanned admissions, within 30 days of discharge.   
Conclusions: 
A significant proportion of newly diagnosed HR or VHR pediatric ALL patients 
experience a prolonged LOS and unplanned re-admissions.  Aggressive discharge 
planning and close follow up is indicated in this cohort of patients. 
 
Abbreviations used:  
WBC  White Blood Cell 
ANC  Absolute Neutrophil Count 
BUN Blood Urea Nitrogen 
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AST Aspartate Aminotransferase 
AST Alanine Aminotransferase 
PT Prothrombin Time 
INR International Normalized Ratio 
OS  Overall Survival 
LFS Leukemia-Free Survival 
ESR  Erythrocyte sedimentation rate  
AM  Ante meridiem (morning) 
SVT  Supra ventricular tachycardia  
APC Absolute phagocytic count  
HR High-risk  
VHR Very high-risk  
PICU Pediatric intensive care unit  
LOS Hospital length-of-stay  
OR Odds-ratio 
ALL Acute lymphoblastic leukemia 
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T-ALL T- Acute lymphoblastic leukemia 
B-ALL B-Acute lymphoblastic leukemia 
MRD Minimal residual disease  
NCI National Cancer Institute  
COG Childrens Oncology Group  
AML  Acute myeloid leukemia  
MLL Mixed lineage leukemia gene 
PEG Pegylated  
iAMP21 Intra-chromosomal amplification of chromosome 21 
ph+  Philadelphia chromosome positive  
ph-like Philadelphia chromosome like 
NA Not available  
N/E Not estimable  
µL Micro-litre  
F/N Febrile neutropenia 
SIADH Syndrome of inappropriate ADH secretion 
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SD Standard deviation  
C.I. Confidence Interval  
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Introduction 
AC
CE
PT
ED
 M
AN
US
CR
IPT
7 
 
Induction chemotherapy results in high remission rate in high risk (HR) and very high 
risk (VHR) childhood acute lymphoblastic leukemia (ALL), but is associated with 
significant morbidity.1,2 HR B-ALL is defined as: white blood cell count (WBC) 
≥50,000/µL or age ≥10 years (National Cancer Institute (NCI) criteria) at presentation, 
or/and central nervous system (CNS) positive leukemia, or testicular leukemia3-5. 
Patients who are >13 years or experience induction failures; and/or if the leukemia 
blasts harbor mixed-lineage leukemia gene (MLL) rearrangements or intrachromosomal 
amplification of chromosome 21 (iAMP21), BCR-ABL translocation, are stratified as very 
high risk (VHR) B-ALL 3,6,7.  Pediatric and young adults with HR, VHR ALL, and T-
lymphoblastic leukemia (T-ALL), are initially treated with a standard 4 drug induction 
regimen2, aimed at achieving a MRD negativity by day 298.  Induction therapy is often 
associated with a high burden of care due to increased therapy-related adverse events 
that require pediatric intensive care unit (PICU) care or a prolonged inpatient length of 
stay (LOS) 9-12.  However, despite standard induction regimens, there is a high 
variability amongst institutions with regards to timing of discharge for patients who 
appear clinically well 13.  We conducted a retrospective, single institutional study with 
the objective to identify risk factors that are associated with a complicated or prolonged 
LOS during induction chemotherapy for pediatric patients (age <21 years) with HR and 
VHR ALL, and to analyze the impact of prolonged length of stay (LOS), on unplanned 
re-admission rates and long term outcomes, in newly diagnosed patients with HR or 
VHR ALL. Our hypothesis was that patients who have shorter LOS have, less frequent 
or severe lab abnormalities, and are less likely to have an unplanned admission during 
induction therapy and a superior survival. Conversely, patients who experienced 
AC
CE
PT
ED
 M
AN
US
CR
IPT
8 
 
prolonged LOS or PICU stay were more likely to have more severe cytopenias, 
increased severity or frequency of lab abnormalities and worse overall survival.  
Materials & Methods 
All patients diagnosed, in 2009-2016 with de novo HR or VHR ALL or T-ALL, and 
treated with a standard 4-drug induction 2 (Vincristine, dexamethasone or prednisone, 
PEG-asparaginase, and duanorubicin) at Riley Children’s Hospital, Indiana University, 
Indianapolis, were included in this, institutional review board approved, retrospective 
study. Ph+ALL patients received tyrosine kinase inhibitors either in induction or in 
consolidation chemotherapy phase. Data was collected on 73 patients from day = 0 
(one day prior to starting induction chemotherapy) through day = 4, by chart review, and 
included both clinical and lab values (normal ranges were established using institutional 
guidelines).  Absolute neutrophil count (ANC) was calculated as 0.01 x (% bands +% 
neutrophils) x total leukocyte count 14. An ANC was determined as ‘rising’ if the mean 
ANC on days 3 and 4 was higher than mean ANC on admission, days 1 and 2.  
 
Statistical Analysis 
Available demographic data was compared across groups using t-tests for continuous 
variables and Chi-Square tests for categorical variables. The patients who had 
readmission within 30 days of discharge were summed and averaged on the number of 
outpatient days and were compared between groups using the Wilcoxon Rank Sum 
test. Rising ANC was compared using the Chi-Square test. Univariable logistic analyses 
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were used to test the lab values on days 0-4 for group B admissions. Additionally, on 
day 4, variables with p-value<0.05 were considered for inclusion in multivariable 
stepwise logistic regression models. Variables with p-values<0.05 were considered 
significant and remained in the model.  Step-wise multivariable was used due to small 
numbers of patients and making sure not to over parameterize the model. 
Kaplan-Meier methods were used for overall survival (OS) and disease (leukemia)-free 
survival (LFS). Overall survival calculated the time from date of diagnosis until date of 
death. If a patient did not die, their values were censored and were calculated from the 
date of diagnosis until the last follow-up date.  LFS was calculated as date of diagnosis 
until first relapse date. If a patient did not relapse, their values were censored and 
calculated as the time from date of diagnosis until the last follow-up date. Comparisons 
were made using the log-rank test. Cox proportional models were used to evaluate the 
significance of each lab value for OS and LFS from day 4 to determine if any variable 
was deemed significant.   
Similar analyses were performed for a subset of lab values for patients on day 4 for 
patients who were admitted to or transferred to the PICU during their hospital stays and 
those patients who were not admitted to or transferred to the PICU.  
SAS version 9.4 (SAS Institute, Cary, NC) was used for analysis. 
 
 
Results  
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Data obtained from clinically well appearing patients, n=42 (group A), who had an initial 
short LOS (4±0 days, discharged after day 4 PEG-asparaginase), was compared to 
data from patients who had a LOS >4 days due to persistent fevers, or lab 
abnormalities, or admission to or transfer to the PICU (n=31, group B, Table 1).  N=42 
(57%) patients (group A) were discharged on day 4 of induction (short LOS), while n=31 
(43%) patients (group B) experienced a prolonged LOS (median hospital stay=8 days vs 
4 days (group A), P=0.02) or an ICU stay (n=13, (18%), (Table 1), due to organ 
dysfunction, infectious or metabolic complications. Only 2 patients (3%) died during 
induction chemotherapy.  There were no differences in age, race, or ethnicity found 
between the two groups (Table 1). Fifteen (36%) of group A patients had adverse 
cytogenetics 15 (ph+ ALL =10, hypodipolid = 3, iAMP21 =2, compared to four (13%) in 
group B (ph+=3, hypodiploid =1) (Table 1, p=0.03).  The higher number of ph+ patients 
(n=13) in our cohort could be due to higher median age and/or due to random variation. 
Eight patients were excluded as they received a 3 drug induction (n=6), had Downs 
Syndrome (N=1) ALL and Munchausen Syndrome (N=1).  Three patients in each group 
had T-ALL and five from each group were transplanted at relapse. Social variables 
(other than race and ethnicity), such as distance from center, affecting LOS and 
physician level factors (e.g bias towards keeping patients for a shorter or longer LOS), 
were not studied in detail due to the retrospective nature of the study. While there were 
no significant differences in this small sample size, and low number of Black (total three, 
group A had one black patient and group B had two) and Asian (only one patient was 
Asian (groupB) patients, non-white patients appeared to be more likely to have a 
delayed discharge and to be admitted to the ICU based on effect size alone. In the 
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subset of patients on whom blood cultures were obtained, no positive blood cultures 
(0/22=0%) were detected during the initial 4 days of admission in group A, while 4/15 
(27%) had positive cultures in group B (p=0.04, TABLE 1). Nineteen (45%) of group A 
patients had a rising ANC, while eleven (35%) of group B patients had a rising ANC by 
days 3 and 4 (p=0.4).   
Group A had higher mean platelet counts (x109/L) on days 0 (day of admission) through 
day 4, higher mean hemoglobin levels on day 4, higher serum bicarbonate on day 4,  
and lower BUN on day 4, compared to group B (Figure 1).   Group B patients had higher 
serum calcium on day 0 and lower serum phosphorus levels on day 1, compared to 
group A (Figure 1). Data is presented graphically only (Figure 1), however, no statistical 
analysis was performed on these raw values due to missing data points (Supplemental 
Table 2S).  No difference in serum lactic dehydrogenase (LDH), liver chemistries (AST, 
ALT), PT, INR, serum albumin and bilirubin), d-dimer, erythrocyte sedimentation rate 
(ESR), absolute blast count, serum sodium and potassium (supplemental data not 
provided for review) or ANC (TABLE 2S) was detected between the two groups.   
On univariable analysis, patients in group B had a higher incidence of fever≥380C on 
day 1 (p= 0.047), were more likely to have a pre-transfusion (AM) hemoglobin <8g/dL 
on days 2 and 3 (p=0.037 and 0.005, respectively), a lower serum bicarbonate values 
on days 2, 3 (p= 0.001, 0.039 respectively), an abnormal serum calcium on days 2 and 
3 (p= 0.006 and 0.017 respectively), and an abnormal serum phosphate on day 3 
(p=0.038)(TABLE 2).  On day 4 of induction chemotherapy (discharge day for all group 
A patients), patients with a pre-transfusion platelet count<20,000 /µL (p=0.037), lower 
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serum bicarbonate (p=0.002), and a higher BUN (p=0.033) were more likely to have a 
prolonged LOS (OR=4.52, 8.21, and 3.02, respectively) (TABLE 2 and TABLE 3).                          
Multivariable stepwise logistic regression identified a low serum bicarbonate (p=0.002) 
and a platelet count<20,000/mm3 (p=0.021) on day 4 of admission to be predictive of a 
prolonged hospital stay (TABLE 3).  
Data from patients who were admitted or transferred to the PICU (n=13) were compared 
to patients who experienced no PICU stay (n=60).  This analysis yielded no significant 
difference in blood counts or laboratory values, LFS and OS between the two groups 
(supplemental data, TABLE S1).   
Sixteen (36%) from group A were readmitted within 30 days of discharge for varied 
indications such as fever, neutropenia, hypotension, fatigue, dehydration, and SVT 
(TABLE 4).  Six of these 16 patients were re-admitted to the PICU (15%).   Eleven 
patients (35%) from group B were readmitted within 30 days of discharge (p=0.8, 
TABLE 1.), of which 3 (10%) were re-admitted to the PICU or transferred to the PICU 
during their re-admission.  The sum of outpatient days eligible for readmission (after 
discharge) were lower in group B compared to group A, but this difference was not  
statistically different (group A had a sum of 170 days (mean±SD, 10.6± 8.3) and group 
B had a sum of 124 days (mean±SD of 11.3± (7.5), (p=0.8)).  Furthermore, at day 35 of 
induction (arbitrary fixed time point), the proportion of “eligible for readmission” sum of 
days in readmitted patients versus patients who did not experience a readmission was 
also not different in the two groups (group A (170/780=0.22) and group B 
(107/450=0.24), (p=0.8)). LFS was significantly worse in group B compared to group A 
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(5 year LFS=58% (group B) vs 89% (group A), p=0.03) (Figure 2). No difference in the 
OS was observed in the two groups (5 year OS=67% (group B) vs 83% (group A), 
p=0.9) (Figure 3). 
Discussion  
Pediatric patients with newly diagnosed ALL often have a high symptom burden and 
significant morbidity during the initial (induction) phase of chemotherapy requiring a 
prolonged hospital stay 9,13.  
Pediatric Oncologists are frequently faced with the challenge of assessing if a newly 
diagnosed HR/VHR ALL patient can be safely discharged home early in their hospital 
stay for induction chemotherapy (usually by day 4).  Due to a lack of published data on 
factors associated with or predictive of a complicated course during induction, the timing 
of discharge is often arbitrary and varies amongst different providers and institutions 13.  
At Riley Hospital for Children, Indianapolis, Indiana, we routinely discharge HR and 
VHR ALL patients on Day 4 of induction chemotherapy, after they receive PEG-Asp, if 
they are afebrile, tolerating oral medications, have completed teaching, deemed 
clinically stable (not toxic appearing) and follow up visit is arranged.   However, other 
institutions have adopted a policy of keeping all newly diagnosed HR and VHR ALL 
patients inpatient for the entire duration of induction chemotherapy 13 or until ANC 
and/or APC is rising16 17 .  Current supportive care guidelines from the Children’s 
Oncology Group (COG) recommend hospitalization for the duration of chemotherapy 
and associated marrow aplasia for patients on phase III AML trial18 but no specific 
guidelines exist for non-Downs syndrome ALL patients.   
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Our study aimed to identify specific criteria that are associated with a complicated 
course during induction in this cohort of patients, by comparing clinical and laboratory 
characteristics during the first four days of induction chemotherapy, between patients 
who were discharged after a brief LOS (discharged on day four of induction 
chemotherapy) (group A) versus patients who experienced a prolonged LOS (>4 days) 
or intensive care unit stay (group B) during induction chemotherapy, to help determine a 
safe discharge plan in these patients. We also compared readmission (within 30 days) 
rates for both groups.  
On univariable analysis (Table 2), more patients with a prolonged LOS (group B) were 
more likely to be febrile, have lower hemoglobin platelet counts, and serum bicarbonate; 
and increased BUN and calcium/phosphate abnormalities.  These findings are indicative 
of an extended need for supportive measures, transfusion requirements for anemia and 
thrombocytopenia, higher likelihood of electrolyte abnormalities, acidosis and organ 
dysfunction, in patients who experience a prolonged LOS.   
Approximately, one third of patients in both groups experienced unplanned 
readmissions within 30 days due to varied reasons.  Despite this high readmission rate, 
we noted a low overall induction mortality of 2.7% (n=2), similar to previously reported 
studies 11,19.   
Patients who were discharged on day 4 of induction treatment (group A) had a higher 5 
year disease (leukemia) free survival (Figure 2, p=0.03), but no difference was noted in 
overall survival.  However, various factors that were not analyzed in this study, such as, 
a higher number of ph+ALL patients in group A necessitating a tyrosine kinase inhibitor 
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during induction and consolidation 20 (ten versus three in group B), an unknown ph-like 
ALL signature 21, timing of transplant, and MRD 15, may have skewed these results.  In 
addition, while treatment delays during the intensive phase of treatment has not be 
shown to impact an increase of relapse 22, nonadherence to treatment during 
maintenance therapy is associated with a significant risk of relapse . It is plausible that 
the inferior LFS in group B was a result of treatment delays 23.  Treatment response and 
post-transplant salvage therapies per se, should not have affected early discharge or 
LOS, as they would not even have occurred yet. These findings underscore the need for 
future large cooperative and prospective studies aimed at studying the impact of longer 
LOS, during induction on LFS in this cohort of patients.  
Recent studies have shown that LOS is longer in newly diagnosed ALL patients (not risk 
stratified) if they are either admitted over the weekend 24,25 and that LOS >7 days is 
ultimately associated with fewer readmissions to the PICU 13.  However, while we did 
not analyze timing of admission (weekend or not), our analysis suggests that LOS does 
not impacts the frequency of unplanned admissions in HR/VHR ALL patients. Patients 
with a longer LOS were as likely to be readmitted, within 30 days, as those with a 
shorter LOS (TABLE 4).  This may be explained by the fact that higher intensity of 
treatment (4 drug induction) is potentially associated with an overall increased incidence 
of complications in this group of patients, often necessitating a readmission, regardless 
of initial short LOS.  
Neutropenia usually results from leukemic infiltration into the bone marrow or from bone 
marrow suppression secondary to ongoing infection at the time of leukemia diagnosis.  
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ANC <200/mm3 has been identified as a risk factor for readmission and infection during 
induction chemotherapy 11,14,26.   However, these studies included both low risk 
(receiving 3-drug induction) and HR/VHR patients in their analysis 14. While degree of 
neutropenia, and/or presence of a rising ANC is often taken into consideration when 
determining a safe discharge, our data suggests that this may not be predictive of 
readmission or LOS in this cohort of HR/VHR ALL patients, as we found no difference in 
ANC and unplanned re-admission within 30 days in the 2 groups.  
Limitations of this study include its retrospective nature and small cohort of patients 
representing a subgroup of newly diagnosed pediatric ALL. This relatively small sample 
of patients may not have allowed adequate power to uncover other laboratory 
abnormalities, performance status, or comorbidities as predictors associated with a 
complicated hospital admission for induction chemotherapy, and needs to be validated 
prospectively and in an independent cohort of similar cases.  Additionally, validation is 
required of the variables examined here, however such as platelets, bicarbonate, fever, 
etc.  A randomized trial to examine these would be ideal, but difficult to accomplish. 
Future directions include prospectively collecting data, during HR/VHR ALL induction 
therapy, to establish discharge criteria based on a scoring algorithm.   
While outpatient management during induction chemotherapy in HR or VHR ALL 
patients is attractive due to reduced costs and improved patient comfort 18, our study 
supports the notion that this may not be the safest option in this group of patients.  AC
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Conversely, an early discharge is safe in a subgroup of patients. Treating physicians 
could opt for a discharge only after normalization of electrolyte abnormalities and renal 
functions, and when no transfusion support is needed (stable hematocrit and platelet 
count).  Nevertheless, after discharge, an aggressive and close outpatient follow up of 
these patients is indicated in these patients, as they remain prone to complications and 
readmissions.    
Conclusions  
A significant proportion of HR and VHR pediatric ALL patients experience a prolonged 
or complicated inpatient hospital stay and readmission during induction chemotherapy. 
We have identified clinical factors and laboratory abnormalities that are associated with 
and may be predictive of a complicated or prolonged hospitalization for induction 
chemotherapy in this population of patients.  Our study supports aggressive discharge 
planning and close follow up, during induction, in this cohort of patients.  
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FIGURE 1. Graphs representing laboratory Values on day 0 (one day prior to starting 
treatment) through day 4 of induction therapy. The A) white blood cell count (WBC, 
(103/µL), B) absolute neutrophil count (ANC, 103/µL), C) platelet count 103/µL, D) 
hemoglobin (grams/dl), E) serum bicarbonate, F) blood urea nitrogen (BUN), G) serum 
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calcium and H) phosphate are depicted in line graphs for each group (blue for group A 
and red for group B).  Mean±SD are depicted by circles and error bars, respectively. 
See table 2S for raw values. 
Abbreviations:  
Pediatric intensive care unit (PICU) 
White blood count (WBC) 
Standard deviation (SD) 
Absolute neutrophil count (ANC) 
Blood urea nitrogen (BUN) 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
22 
 
 
FIGURE 2. Leukemia-Free Survival in patients discharged on day 4 (group A, short 
length of stay = 4 days, depicted in blue graph) versus patients who experienced a 
prolonged hospital stay or PICU admission during after diagnosis (group B, red). 
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FIGURE 3.  Overall Survival in patients discharged on day 4 (group A, short length of 
stay = 4 days, depicted in blue graph) versus patients who experienced a prolonged 
hospital stay or PICU admission during after diagnosis (group B, red).   
 
 
 
 
 
Legend: 
 
TABLE 1. Patient characteristics of Group A (short LOS=4 days) compared to patients 
with a prolonged LOS or PICU admission) (Group B). *p-value from Chi-square test for 
categorical variables and from t-test for continuous variables 
Abbreviations: 
Length-of-stay (LOS) 
Pediatric intensive care unit (PICU) 
White blood count (WBC) 
Standard deviation (SD) 
 
 
TABLE 1.  
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Variable                                         
Mean±SD (% or median) Group A (N=42) Group B (N=31) 
p-
value  
Sex    
Female 10 (24%) 10 (32%) 0.4 
Male 32 (76%) 21 (68%)  
    
Race and ethnicity    
Non-White 1 (2%) 3(9.6%) 0.3 
White 41 (98%) 28 (90.3%)  
    
Hispanic or Latino 8 (19%) 4 (13%) 0.5 
Not Hispanic or Latino 34 (81%) 27 (87%)  
    
Age at Diagnosis 12.1±4.9 (13.5) 14.1±4.2 (15) 0.08 
    
Length of Stay (LOS) (days) 4±0 (4) 16±27.7 (8) 0.02 
    
Readmission within 30 days 16 (38%) 11 (35%) 0.8 
    
WBC at presentation 46.0±75.3 (19.5) 114.6±197.0 (37.2) 0.1 
    
Positive Blood Culture 0/22 (0%) 4/15 (26%) 0.04 
    
High Risk Cytogenetics 15 (36%) 4 (13%) 0.03 
 
 
TABLE 2. Univariable analysis of clinical and lab data for Days 0-4. **N/E = value is not 
estimable, due to either all, or almost all values being within one category. 
Abbreviations: 
White blood count (WBC) 
Absolute neutrophil count (ANC) 
Blood urea nitrogen (BUN) 
Not estimable (N/E) 
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TABLE 2.  
 
Variable 
 
 
Day=0 
 
 
Day=1 
 
Day=2 
 
Day=3 
 
Day=4 
 
Group 
 
 
A 
 
B 
 
A 
 
B 
 
A 
 
B 
 
A 
 
B 
 
A 
 
B 
 
WBC 
 
 
46.0±75.
3  
[31] 
 
 
114.6± 
197.0 
[25] 
 
27.4±45.
4  
[29] 
 
75.1±127
.0 
[28] 
 
16.5±31.0  
[30] 
 
40.5±72.
9 
[25] 
 
7.6±16.3  
[30] 
 
9.1±23.7 
[30] 
 
3.3±8.5  
[32] 
 
2.3±3.4 
[30] 
 
ANC 
 
 
3277±55
25  
[42] 
 
 
3831±79
68 
[31] 
 
 
2355±41
80  
[40] 
 
2134±39
47 
[30] 
 
2660±463
4)  
[39] 
 
1813±33
83 
[31] 
 
2833±44
17 
[39] 
 
1841±38
27 
[31] 
1939 
±2533 
[41] 
1094±19
89 
[31] 
 
Platelet 
count 
 
103±99  
 
46.4±47.
3 
 
101±71  
 
65.8±39.
9 
 
105.2±75 
 
63.1±35.
4 
 
106.6±88
.5 
 
54.6±36.
9 
 
102.2±89
.5 
 
48.5±39.
2 
 [41] 
 
[31] [39] [30] [40] [31] [40] [31] [38] [31] 
 
Hemoglob
in 
 
7.9±2.4 
 
7.8±3.2 
 
8.6±1.1  
 
8.8±1.5 
 
9.2±1.4  
 
9.0±1.4 
 
9.0±1.3 
 
8.6±1.5  
9.5±1.4 
 
8.7±1.4 
 [32] 
 
[27] [34] [28] [35] [29] [36] [31] [41] [31] 
 
Bicarbona
te 
 
22.2±4.8 
 
24.6±4.4 
 
21.3±6.6 
 
23.7± 3.8 
 
24.4±1.8 
 
24.1±3.5 
 
24.2±2.1 
 
23.3±2.9 
 
24.2±2.2 
 
22.8±2.6 
 [9] 
 
[14] [4] [19] [42] [31] [42] [31] [42] [[31] 
 
BUN 
 
22.0±1.4 
 
16.9± 8.0 
 
NA 
 
17.9± 
16.1 
 
25.0±5.0 
 
23.7±16.
3 
 
26.8±5.8 
 
29.5±20.
2 
 
15.4±6.4 
 
24.6±16.
6 
 
[5] 
 
[15] 
 
 
[14] [4] [15] [6] [16] [42] [31] 
 
Calcium  
8.3±0.1 
 
9.0±1.2 
 
7.8±1.5 
 
8.5±1.3 
 
8.7±0.5 
 
8.3±0.9 
 
8.8±0.6 
 
8.3±1.1 
 
8.0±0.4 
 
8.0±1.2 
 
[5] 
 
[19] 
 
[12] 
 
[20] [42] [31] [42] [31] [10] [20] 
 
 
Phosphat
e 
 
5.3±1.1 
 
4.1±2.4 
 
6.0±0.6 
 
4.7±1.7 
 
4.6±2.3 
 
5.1± (2.0 
 
5.5±1.8 
 
5.3±2.7 
 
5.6±1.1 
 
5.3± 3.1 
 [5] 
 
[16] 
 
[17] 
 
[21] [12] [20] [7] [18] [10] [17] 
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TABLE 3. Results of the univariable and multivariable logistic regression.  30 variables 
were analyzed as potential predictors of prolonged hospital stay, and step-wise 
multivariable analysis was performed using the univariable results with p<0.05 (using at 
most 4 variables due to the small sample size).  Age, sex, fever, and other lab values 
had p≥0.05 and were not included in the step-wise multivariable model. 
Abbreviations: 
Blood urea nitrogen  
Confidence interval (C.I.) 
 
 
TABLE 3. 
 
 
 
TABLE 4: Blood counts (Absolute neutrophil count (ANC) (103/µL), pre-transfusion 
hemoglobin (grams/dl) and platelet count (103/µL)) on Day 4 of induction chemotherapy 
Variable Comparison  Univariate1   Multivariate   
  Odds Ratio (95% C.I.) p-value 
Odds Ratio 
(95% C.I.) p-value 
            
Bicarbonate Abnormal vs Normal 8.21 (2.07, 32.6) 0.002 
9.71             
(2.35, 40.12) 0.0017 
            
BUN Abnormal vs Normal 3.02 (1.09, 8.39) 0.033   
            
Calcium Abnormal vs Normal 2.64 (0.97, 7.18) 0.058   
            
Platelets  <20,000 vs >=20,000 4.52 (1.09, 18.76) 0.037 
5.86              
(1.31, 26.18) 0.0205 
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for group A and B patients who had an unplanned re-admission within 30 days of 
discharge. *p-value from t-test for continuous variables.  
 
Abbreviations:  
Absolute neutrophil count (ANC) 
Fever and neutropenia (F/N) 
Syndrome of inappropriate ADH secretion (SIADH) 
Standard deviation (SD) 
TABLE 4. 
Group Reason for Unplanned admission  ANC Hemoglobin Platelet count  
A (n=16 = 36%) Diarrhea 192 9.6 73 
 F/N 155 9.7 42 
 F/N 11880 9.3 61 
 F/N 88 NA 124 
 F/N 150 8 32 
 Fatigue, decreased appetite 820 9.2 26 
 Diarrhea, dehydration 4545 8.6 67 
 Pain control 1403 11.6 242 
 Septic shock NA 7.8 302 
 Dehydration 160 8.4 10 
 F/N 1197 9.6 49 
 Septic shock 852 9.7 44 
 Dehydration 2697 12 185 
 Abscesses 0 7.6 78 
 Abdominal pain, transaminitis 945 11 101 
 Sinus venous thrombosis 17 9.8 248 
Mean±SD  1673±3081 9.5±1.2 105.3±89.9 
     
B (n=11 = 35%) SIADH 496 9.7 146 
 Coagulopathy 1530 8.4 38 
 F/N 108 11.1 24 
 F/N 28 10.2 49 
 F/N 336 8.4 53 
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 F/N 40 6.8 61 
 Abdominal pain  220 8.7 107 
 Cachexia 1280 9.4 45 
 Septic Shock  1420 8.5 69 
 Bleeding 3922 8.6 16 
 Increasing blast count 715 7.9 91 
Mean±SD  917.7±1142 8.9±1.2 63.5±38.2 
p-value*  0.4 0.3 0.1 
AC
CE
PT
ED
 M
AN
US
CR
IPT
